International Journal of Clinical Oncology

, Volume 22, Issue 3, pp 607–608 | Cite as

Reply to comments from Vincent et al.

Letter to the Editor
  • 56 Downloads

References

  1. 1.
    Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003CrossRefPubMedGoogle Scholar
  2. 2.
    Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586CrossRefPubMedGoogle Scholar
  3. 3.
    Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671CrossRefPubMedGoogle Scholar
  4. 4.
    Hira D, Chisaki Y, Noda S et al (2015) Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 96:90–98CrossRefPubMedGoogle Scholar
  5. 5.
    Mayer MD, Khosravan R, Vernillet L et al (2005) Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12:22–34CrossRefPubMedGoogle Scholar
  6. 6.
    The Japanese Societyof Medical Oncology (ed) (2013) Clinical practice guideline for tumor lysis syndrome. Kanehara Shuppan, TokyoGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.General Medical Research Center, Faculty of MedicineFukuoka UniversityFukuokaJapan

Personalised recommendations